Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Absci Corporation - Common Stock (NQ: ABSI )

5.820 +0.820 (+16.40%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Absci Corporation - Common Stock

< Previous 1 2 3 Next >
Absci to Participate in the Guggenheim Securities SMID Cap Biotech Conference
From Absci Corporation
Via GlobeNewswire
Absci and Owkin Synergize Leading TechBio Platforms to Advance Generative AI Drug Discovery
Collaboration combines Owkin’s novel AI target discovery and agentic AI expertise with Absci’s leading AI de novo design models to accelerate the discovery and design of potential first-in-class... 
From Absci Corporation; Owkin
Via GlobeNewswire
Absci and AMD Announce Collaboration and Strategic Investment to Accelerate the Future of AI Drug Discovery
$20 Million Equity Investment from AMD Strengthens Absci’s Leadership in AI Drug Discovery and Further Expands Biopharma Adoption of AMD Instinct Accelerators and ROCm Software 
From Absci Corporation
Via GlobeNewswire
Absci and Invetx Partner to Bring Generative AI Drug Creation Platform to Animal Health
Collaboration leverages Absci’s leading generative AI Drug Creation models to design a novel antibody Half-Life Extension (HLE) platform for animal health applications 
From Absci Corporation; Invetx
Via GlobeNewswire
Absci to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
From Absci Corporation
Via GlobeNewswire
Absci Highlights Progress and Updates Across Proprietary Pipeline and Leading AI Platform at 2024 R&D Day
From Absci Corporation
Via GlobeNewswire
Absci to Participate in the 36th Annual Piper Sandler Healthcare Conference
From Absci Corporation
Via GlobeNewswire
Absci Reports Business Updates and Third Quarter 2024 Financial and Operating Results
From Absci Corporation
Via GlobeNewswire
Absci to Host R&D Day on December 12, 2024
From Absci Corporation
Via GlobeNewswire
Absci and Twist Bioscience Collaborate to Design Novel Antibody using Generative AI
Collaboration brings together Absci’s Generative AI drug creation platform with Twist’s DNA synthesis platform to accelerate the design of a novel therapeutic antibody 
From Absci Corporation
Via GlobeNewswire
Absci to Participate in Upcoming Investor Conferences
From Absci Corporation
Via GlobeNewswire
Absci to Report Business Updates and Third Quarter 2024 Financial and Operating Results on November 12, 2024
From Absci Corporation
Via GlobeNewswire
Absci to Participate in Upcoming Investor Conferences
From Absci Corporation
Via GlobeNewswire
Absci Reports Business Updates and Second Quarter 2024 Financial and Operating Results
From Absci Corporation
Via GlobeNewswire
Absci Collaborates with Global Cancer Center to Discover Novel Therapeutics Using Generative AI
The collaboration unites Absci’s Generative AI Drug Creation Platform with leading oncology experts to co-develop up to six novel cancer therapeutics 
From Absci Corporation
Via GlobeNewswire
Absci to Report Business Updates and Second Quarter 2024 Financial and Operating Results on August 14, 2024
From Absci Corporation
Via GlobeNewswire
Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Absci Corporation
Via GlobeNewswire
Absci to Participate in the Morgan Stanley 3rd Annual Life Sciences AI Summit
From Absci Corporation
Via GlobeNewswire
Absci to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
From Absci Corporation
Via GlobeNewswire
Absci Reports Business Updates and First Quarter 2024 Financial and Operating Results
From Absci Corporation
Via GlobeNewswire
Absci to Report Business Updates and First Quarter 2024 Financial and Operating Results on May 14, 2024
From Absci Corporation
Via GlobeNewswire
Absci to Participate in the 23rd Annual Needham Virtual Healthcare Conference
From Absci Corporation
Via GlobeNewswire
Absci Reports Business Updates and Fourth Quarter and Full Year 2023 Financial and Operating Results
From Absci Corporation
Via GlobeNewswire
Absci Announces Closing of Public Offering of Common Stock Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
From Absci Corporation
Via GlobeNewswire
Absci Announces Pricing of Public Offering of Common Stock
From Absci Corporation
Via GlobeNewswire
Absci Announces Proposed Public Offering of Common Stock
From Absci Corporation
Via GlobeNewswire
Absci Initiates IND-Enabling Studies for ABS-101, a Potential Best-in-Class Anti-TL1A Antibody de novo Designed and Optimized Using Generative AI
IND submission expected in Q1 2025; Phase 1 trials anticipated to initiate shortly after 
From Absci Corporation
Via GlobeNewswire
Absci to Participate in Upcoming Investor Conferences
From Absci Corporation
Via GlobeNewswire
Absci Appoints Professor Sir Mene Pangalos to its Board of Directors
From Absci Corporation
Via GlobeNewswire
Absci to Present Preclinical Data for ABS-101, A Potential Best-in-Class Anti-TL1A Antibody Development Program, at 42nd Annual J.P. Morgan Healthcare Conference
From Absci Corporation
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.